Half-life
30 min
Shoemaker CIRS Protocol: final step for mold/biotoxin-related Chronic Inflammatory Response Syndrome — corrects TGF-β1, C4a, MMP9 refractory to other therapies. Autoimmune, COPD, pulmonary hypertension, IBD research. Endogenous neuropeptide with FDA-approved analogs.
28-AA linear neuropeptide; C-terminal amidation for stability. Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2. Binds VPAC1 and VPAC2 receptors (Gαs) → adenylate cyclase → cAMP/PKA. Anti-inflammatory: inhibits TNF-α, IL-6, IL-1β. Modulates Th1/Th2/Th17/Treg balance. Intranasal: olfactory/trigeminal pathway for direct brain access.
VPAC1/VPAC2 agonism; Shoemaker CIRS protocol (final step); NF-κB inhibition; intranasal CNS delivery; 30-min half-life; autoimmune modulation; TGF-β1/C4a correction.
Research data is not a treatment plan. If you are considering VIP (Vasoactive Intestinal Peptide), the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals